Literature DB >> 431488

Influenza virus infection of the guinea pig: immune response and resistance.

J P Phair, C A Kauffman, R Jennings, C W Potter.   

Abstract

Guinea pigs were inoculated by intranasal inoculation with unadapted, influenza virus A/England/42/72, and virus was recovered from nasal washings between 3 and 10 days post-inoculation. Infected animals did not exhibit a febrile response to infection, did not produce local antibody and produced only relatively low levels of serum antibody. However, they developed delayed-type hypersensitivity to influenza virus, demonstrable by both skin tests and macrophage migration inhibition tests, which was similar to that of man. The relevance of the influenza virus specific delayed hypersensitivity in immunity to infection was examined in this model. Guinea pigs previously infected with virus or passively immunized with hyperimmune serum were relatively resistant to reinfection with influenza virus A/England/42/72. Inoculation of guinea pigs with spleen cells from immune donor animals, together with or without immune serum, did not give or enhance resistance to challenge virus infection. The results do not suggest a role for delayed hypersensitivity response in immunity to influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 431488     DOI: 10.1007/bf02152923

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  18 in total

1.  An improved assay method for neutralizing antibodies against influenza viruses.

Authors:  S F DE ST GROTH; J WITHELL; K J LAFFERTY
Journal:  J Hyg (Lond)       Date:  1958-09

2.  Immunity to influenza in ferrets. I. Response to live and killed virus.

Authors:  C W Potter; J S Oxford; S L Shore; C McLaren; C Stuart-Harris
Journal:  Br J Exp Pathol       Date:  1972-04

3.  Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine.

Authors:  R H Waldman; J J Mann; P A Small
Journal:  JAMA       Date:  1969-01-20       Impact factor: 56.272

4.  Immune response of the human respiratory tract. II. Cell-mediated immunity in the lower respiratory tract to tuberculin and mumps and influenza viruses.

Authors:  P F Jurgensen; G N Olsen; J E Johnson; E W Swenson; E M Ayoub; C S Henney; R H Waldman
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

5.  Production of rubella hemagglutinating antigen in suspension cultures.

Authors:  G L Gitnick; M M Vincent; A Auletta; A Ley; N Tzan; J L Sever
Journal:  Appl Microbiol       Date:  1967-09

6.  Influenza infection in ferrets: role of serum antibody in protection and recovery.

Authors:  P A Small; R H Waldman; J C Bruno; G E Gifford
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

7.  Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2 ) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines.

Authors:  D S Freestone; S Hamilton-Smith; G C Schild; R Buckland; S Chinn; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1972-09

8.  Host defenses against influenza virus: the role of anti-hemagglutinin antibody.

Authors:  J L Virelizier
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

9.  Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines.

Authors:  C McLaren; C W Potter
Journal:  J Hyg (Lond)       Date:  1974-02

10.  INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

Authors:  J L SCHULMAN; E D KILBOURNE
Journal:  J Bacteriol       Date:  1965-01       Impact factor: 3.490

View more
  9 in total

1.  Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein.

Authors:  Ruth V Bushnell; John K Tobin; Jinxue Long; Stacey Schultz-Cherry; A Ray Chaudhuri; Peter L Nara; Gregory J Tobin
Journal:  Virol J       Date:  2010-08-24       Impact factor: 4.099

Review 2.  Animal models for influenza virus transmission studies: a historical perspective.

Authors:  Nicole M Bouvier
Journal:  Curr Opin Virol       Date:  2015-06-28       Impact factor: 7.090

3.  Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

Authors:  Sabine Sereinig; Marina Stukova; Natalia Zabolotnyh; Boris Ferko; Christian Kittel; Julia Romanova; Tatiana Vinogradova; Hermann Katinger; Oleg Kiselev; Andrej Egorov
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  The guinea pig as a transmission model for human influenza viruses.

Authors:  Anice C Lowen; Samira Mubareka; Terrence M Tumpey; Adolfo García-Sastre; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

5.  Animal Models for Influenza Virus Pathogenesis and Transmission.

Authors:  Nicole M Bouvier; Anice C Lowen
Journal:  Viruses       Date:  2010       Impact factor: 5.048

Review 6.  Influenza antivirals and animal models.

Authors:  C Joaquin Caceres; Brittany Seibert; Flavio Cargnin Faccin; Stivalis Cardenas-Garcia; Daniela S Rajao; Daniel R Perez
Journal:  FEBS Open Bio       Date:  2022-04-27       Impact factor: 2.792

Review 7.  Animal Models for Influenza Research: Strengths and Weaknesses.

Authors:  Thi-Quyen Nguyen; Rare Rollon; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

Review 8.  Animal models for influenza virus pathogenesis, transmission, and immunology.

Authors:  Rajagowthamee R Thangavel; Nicole M Bouvier
Journal:  J Immunol Methods       Date:  2014-04-04       Impact factor: 2.303

Review 9.  Transmission in the guinea pig model.

Authors:  Anice C Lowen; Nicole M Bouvier; John Steel
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.